New Guidance from The National Inpatient Diabetes COVID19 Response Group
The National Inpatient Diabetes COVID19 Response Group has published guidance for healthcare professionals on managing hyperglycaemia/diabetes in a COVID Virtual Ward for patients with or without diabetes. This is to support safe management of hyperglycaemia in those receiving glucocorticoid treatment for COVID-19 infection outside of a hospital environment.
JBDS 18 COncise adVice on Inpatient Diabetes (COVID:Diabetes) - Hyperglycaemia
COncise adVice on Inpatient Diabetes (COVID:Diabetes): Hyperglycaemia/diabetes Guidance For People With COVID-19 Infections Managed In A Virtual Ward: A Guide For Healthcare Professionals
RT-CGM and flash glucose monitoring not recognised By DVLA for G2 Drivers with Insulin Treated Diabetes
The use of technologies to monitor diabetes is expanding rapidly. The flash glucose monitoring (FSL) is allowed for clinical use in selected group of individuals with type 1 Diabetes in the UK.
In GB, there are 1428 drivers with type 1 Diabetes who currently hold a Group 2 (lorry and bus) Driving licence. The regulation to allow insulin treated individuals with diabetes to drive, was allowed, several years ago when UK was an EU member.
Canagliflozin use in patients with reduced renal function at baseline is still associated with significant improvements in multiple parameters: results from the Association of British Clinical Diabetologists (ABCD) canagliflozin audit
TSJ Crabtree1,2,3, K Dhatariya4, D Sennik5, A Rohilla5, S Sivappriyan6, D Barnes6, S Soo6, I Gallen7, REJ Ryder1 on behalf of ABCD canagliflozin audit contributors9
1. Sandwell and West Birmingham Hospitals NHS Trust
2. University Hospitals of Derby and Burton NHS Trust
3. University of Nottingham
4. Norfolk and Norwich NHS Trust
5. Princess Alexandra Hospital NHS Trust; West Essex CCG
6. Maidstone and Tunbridge Wells NHS Trust
The impact of empagliflozin on eGFR and albuminuria: results from the ABCD nationwide empagliflozin audit
TSJ Crabtree1,2,3, J Elliott4, A Bickerton5, A Evans6, S Phillips6, K Dhatariya7, I Gallen8, REJ Ryder1; on behalf of ABCD empagliflozin audit contributors9
1 Sandwell and West Birmingham Hospitals NHS Trust
2 University Hospitals of Derby and Burton NHS Trust
3 University of Nottingham
4. Sheffield Teaching Hospitals NHS Trust
5 Yeovil District Hospitals NHS Foundation Trust
6 Gloucestershire Hospitals NHS Trust
Invitation for trainee in diabetes and endocrinology to join the ABCD academic sub-committee
The newly formed ABCD academic subcommittee are inviting applications from trainees in diabetes and endocrinology to join their board.
On Demand Webinar: Using diabetes Apps to help with diagnosis and treatment decisions
This is the third of our 2021 ABCD webinar series which run on the first Thursday of each month.
We are looking for a junior doctor to join JBDS
Junior doctors are invited to apply for a position with the Joint British Diabetes Societies for Inpatient Care (JBDS). This unremunerated post is designed to help refresh and update the existing guidelines that have been produced so far (all found at https://abcd.care/joint-british-diabetes-societies-jbds-inpatient-care-group), but also to help JBDS appreciate the needs of junior doctors.
